Enveric Biosciences Discusses Acquisition of Exclusive License from Diverse Biotech and Value Catalysts Moving Forward in New Video Interview on SNN Network
LOS ANGELES, CA / ACCESSWIRE / March 17, 2021 / SNN Network, The Official Small-, Micro- and Nano-Cap News Source™, today published a new Video Interview with David Johnson, Chairman, and CEO of Enveric Biosciences (NASDAQ:ENVB), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, according to the company's website (see here: www.enveric.com).
Click the following link to watch the Video Interview:
You can follow SNN Network on FACEBOOK, TWITTER, LINKEDIN, YOUTUBE
Please review important disclosures on our website at http://stocknewsnow.com/legal.php#disclaimer
About Enveric Biosciences
Enveric Biosciences is a patient-first biotechnology company developing rigorously tested, novel cannabinoid medicines to improve quality of life for cancer patients. Initial indications include radiodermatitis, a common and often severe side effect of radiation therapy, and chemotherapy-induced neuropathy. For more information, please visit https://www.enveric.com/.
About SNN Network
SNN Network is an investor portal covering the Small-, Micro- and Nano-cap markets by providing news, insights, education tools, and expert commentary. Subscribe now to our YouTube Channel to be notified when new CEO video interviews, Wall Street Views with investing experts, and Planet MicroCap Podcast episodes are available.
Subscribe NOW to SNN Network: http://bit.ly/1Q5Yfym
CONTACT:
SNN Network
info@snnwire.com
SOURCE: Enveric Biosciences Inc.
View source version on accesswire.com:
https://www.accesswire.com/636051/Enveric-Biosciences-Discusses-Acquisition-of-Exclusive-License-from-Diverse-Biotech-and-Value-Catalysts-Moving-Forward-in-New-Video-Interview-on-SNN-Network
